Detalles de la búsqueda
1.
Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers.
Antimicrob Agents Chemother
; 67(4): e0162322, 2023 04 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36988461
2.
Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial.
Antimicrob Agents Chemother
; 67(5): e0141922, 2023 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37022196
3.
Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial.
J Antimicrob Chemother
; 78(10): 2471-2480, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37596890
4.
Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder.
J Psychiatr Res
; 68: 392-6, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26025562
5.
A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of Major Depressive Disorder.
J Psychiatr Res
; 47(7): 944-54, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23562150
6.
An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery.
J Psychiatr Res
; 46(12): 1553-63, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22998742
Resultados
1 -
6
de 6
1
Próxima >
>>